Design of Multiplex Lateral Flow Tests: A Case Study for Simultaneous Detection of Three Antibiotics

Bartosh, Anastasiya V.; Sotnikov, Dmitriy V.; Hendrickson, Olga D.; Zherdev, Anatoly V.; Dzantiev, Boris B.

doi:10.3390/bios10030017

Cited by 21 publications

(13 citation statements)

References 34 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LFAs intended as SARS-CoV-2 serology assays often test for both IgG and IgM antibodies immobilized in spatially distinct zones. Aside from the choice in nitrocellulose membrane as a function of capillary flow rate, there are design considerations to placement of the LFA lines, with respect to the altered binding kinetics that occur over the length of the nitrocellulose membrane [ 106 , 107 ]. When immobilized adjacent to the sample pad, a relatively large amount of fluid is available and hence fluid flow through the test line is at its greatest.…”

Section: Challenges With Serology Assay Development and Implementatiomentioning

confidence: 99%

“…When immobilized adjacent to the sample pad, a relatively large amount of fluid is available and hence fluid flow through the test line is at its greatest. As fluid passes further up the membrane towards the absorbent pad, evaporation from the surface and depletion of fluid from the reservoir causes fluid flow to slow [ [106] , [107] , [108] , [109] ]. These altered kinetics affect the duration of the interaction with the immobilized species, having an impact on the limit of detection of these assays as well as the increasing the potential for non-specific interactions as the fluid flow is reduced [ 106 ].…”

Section: Challenges With Serology Assay Development and Implementatiomentioning

confidence: 99%

See 1 more Smart Citation

Technical considerations to development of serological tests for SARS-CoV-2

Ernst

Wolfe

Stahura

et al. 2021

Talanta

View full text Add to dashboard Cite

Section: Challenges With Serology Assay Development and Implementatiomentioning

confidence: 99%

Section: Challenges With Serology Assay Development and Implementatiomentioning

confidence: 99%

Technical considerations to development of serological tests for SARS-CoV-2

Ernst

Wolfe

Stahura

et al. 2021

Talanta

View full text Add to dashboard Cite

“…Its application spans from healthcare to farming hazard assessment, by screening disease-relevant biomarkers, bacteria, viruses, toxins, contaminants and so forth [ 3 , 4 ]. In the last decade, the increasing demand for simultaneous detection of multiple biomarkers in a single assay, has resulted in the development of unnumbered multiplexed LFIAs [ 5 , 6 , 7 , 8 ]. In a typical multi-target LFIA, the number of information items corresponds to the number of test lines drawn on the strip.…”

Section: Introductionmentioning

confidence: 99%

Switching from Multiplex to Multimodal Colorimetric Lateral Flow Immunosensor

Cavalera

Nardo

Forte³

et al. 2020

Sensors

View full text Add to dashboard Cite

Multiplex lateral flow immunoassay (LFIA) is largely used for point-of-care testing to detect different pathogens or biomarkers in a single device. The increasing demand for multitargeting diagnostics requires multi-informative single tests. In this study, we demonstrated three strategies to upgrade standard multiplex LFIA to multimodal capacity. As a proof-of-concept, we applied the strategies to the differential diagnosis of Human Immunodeficiency Virus (HIV) infection, a widespread pathogen, for which conventional multiplex LFIA testing is well-established. In the new two-parameter LFIA (x2LFIA), we exploited color encoding, in which the binding of multiple targets occurs in one reactive band and the color of the probe reveals which one is present in the sample. By combining the sequential alignment of several reactive zones along the membrane of the LFIA strip and gold nanoparticles and gold nanostars for the differential visualization, in this demonstration, the x2LFIA can furnish information on HIV serotype and stage of infection in a single device. Three immunosensors were designed. The use of bioreagents as the capturing ligand anchored onto the membrane or as the detection ligand labelled with gold nanomaterials affected the performance of the x2LFIA. Higher detectability was achieved by the format involving the HIV-specific antigens as capturing agent and labelled secondary bioligands (anti-human immunoglobulins M and protein G) as the probes.

show abstract

“…LFAs have been shown to be feasible for use in sub-Saharan African settings and accurate across four orders of magnitude, without the need for a cold chain for distribution or storage ( 6 ). Multiplexing technology is also emerging for LFAs, with multiple proteins either being detected in series, along one strip ( 48 , 49 ), or in parallel, with multiple strips contained within one handheld device ( 50 ).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Host Serum Protein Biomarkers of Tuberculosis in sub-Saharan Africa

et al. 2021

View full text Add to dashboard Cite

Accurate and affordable point-of-care diagnostics for tuberculosis (TB) are needed. Host serum protein signatures have been derived for use in primary care settings, however validation of these in secondary care settings is lacking. We evaluated serum protein biomarkers discovered in primary care cohorts from Africa reapplied to patients from secondary care. In this nested case-control study, concentrations of 22 proteins were quantified in sera from 292 patients from Malawi and South Africa who presented predominantly to secondary care. Recruitment was based upon intention of local clinicians to test for TB. The case definition for TB was culture positivity for Mycobacterium tuberculosis; and for other diseases (OD) a confirmed alternative diagnosis. Equal numbers of TB and OD patients were selected. Within each group, there were equal numbers with and without HIV and from each site. Patients were split into training and test sets for biosignature discovery. A nine-protein signature to distinguish TB from OD was discovered comprising fibrinogen, alpha-2-macroglobulin, CRP, MMP-9, transthyretin, complement factor H, IFN-gamma, IP-10, and TNF-alpha. This signature had an area under the receiver operating characteristic curve in the training set of 90% (95% CI 86–95%), and, after adjusting the cut-off for increased sensitivity, a sensitivity and specificity in the test set of 92% (95% CI 80–98%) and 71% (95% CI 56–84%), respectively. The best single biomarker was complement factor H [area under the receiver operating characteristic curve 70% (95% CI 64–76%)]. Biosignatures consisting of host serum proteins may function as point-of-care screening tests for TB in African hospitals. Complement factor H is identified as a new biomarker for such signatures.

show abstract

Design of Multiplex Lateral Flow Tests: A Case Study for Simultaneous Detection of Three Antibiotics

Cited by 21 publications

References 34 publications

Technical considerations to development of serological tests for SARS-CoV-2

Technical considerations to development of serological tests for SARS-CoV-2

Switching from Multiplex to Multimodal Colorimetric Lateral Flow Immunosensor

Evaluation of Host Serum Protein Biomarkers of Tuberculosis in sub-Saharan Africa

Contact Info

Product

Resources

About